In vitro evaluation of A-56619 and A-56620, two new quinolones | Zendy

A L Barry | Zendy; C Thornsberry | Zendy; Ronald N. Jones | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro evaluation of A-56619 and A-56620, two new quinolones

Author(s) -

A L Barry,

C Thornsberry,

Ronald N. Jones

Publication year - 1986

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.29.1.40

Subject(s) - ofloxacin , norfloxacin , enoxacin , ciprofloxacin , fleroxacin , microbiology and biotechnology , antibacterial agent , pseudomonas , anaerobic bacteria , quinolone , chloramphenicol , biology , antibiotics , chemistry , bacteria , genetics

The in vitro activities of two new aryl-fluoroquinolones (A-56619 and A-56620) were compared with those of ciprofloxacin, ofloxacin, enoxacin, and norfloxacin. All six quinolones had broad spectra of antibacterial activity; the streptococci, Pseudomonas maltophilia, and Pseudomonas cepacia were the least susceptible. A-56619, A-56620, and chloramphenicol had similar activity against anaerobic bacteria. With both drugs, a low frequency of resistant variants (less than 10(-8)) was observed. By regression analysis, A-56619 MICs correlated best with ofloxacin MICs and A-56620 was most similar to ciprofloxacin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research